Renaissance Capital logo

EOM Pharmaceutical Holdings Filed, US Offering, Nasdaq: EOM

Developing in-licensed therapies for inflammatory and ocular diseases.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Our development pipeline consists of multiple programs and clinical indications at various stages of development. Our portfolio currently consists of two product candidates: EOM613 and EOM147. EOM613 is an investigational, dynamically dual-acting immunomodulator. EOM 147 is an investigational, broad-spectrum aminosterol with a novel intracellular mechanism for the treatment of retinal diseases.
more less
IPO News for EOM Pharmaceutical Holdings
more
IPO Data
IPO File Date 06/24/2022
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Montvale, NJ
Founded 2020
Employees 3
Website www.eompharma.com